# Interim Report, Q1 2022

May 11, 2022

bioporto

© Copyright BioPorto

# Forward-Looking Statements

*References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the "Company" or "BioPorto"), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.*

*This presentation contains forward-looking statements. Words such as "believe", "expect", "may", "plan", "strategy", "estimate", "target" and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto's control. These risks and uncertainties are described from time to time in BioPorto's Announcements and in its 2021 Annual Report under Risk Factors. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.*

*This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.*

© Copyright BioPorto

# Agenda

01. Highlights from Q1 2022
02. The NGAL Test Regulatory Studies
03. Q1 2022 financial result
04. Financial Guidance 2022

# Highlights from Q1 2022

© Copyright BioPorto

# Highlights from Q1 2022

- Strong performance of The NGAL Test – US RUO sales up 116% and global sales up 70% compared to Q1 2021
- Completion of pediatric patient enrollment for US FDA submission on-track for end of Q2 2022
- Strategic focus on preparing BioPorto for US breakthrough
- Fully subscribed share offering provides DKKm 93 in net proceeds and runway for strategic execution



© Copyright BioPorto

# Launch an FDA Approved Product in the US

## Strategic Focus

### Drive NGAL Test Market Adoption & Have a Pipeline of High Medical Value Products

- Complete clinical trials & submit The NGAL Test to FDA
- Grow rest-of-world revenues and NGAL awareness through focused distribution resources and tools
- Build US commercialization team to market the clinical value of the NGAL biomarker, and nurture key relationships at target accounts
- Leverage our antibody library and university relationships to cost-effectively build the innovation pipeline

### Strengthen the Company to Scale & Execute

- Strengthen our key supplier relationships and implement scalable manufacturing processes
- Build robustness and ensure Quality Systems are FDA and IVDR audit-ready
- Prepare business processes for efficient and scalable growth

### Attract, Develop & Retain the Best and Brightest Employees Aligned with our Values

- Proactively recruit the most qualified talent to drive success
- Embrace flexible work environments enabling the ability to recruit from a larger pool of candidates
- Motivate and incentivize employees to stay & build shareholder value

© Copyright BioPorto

# Pediatric Trial Enrollment On-track to be Completed end-Q2 2022, To Be Followed by FDA Submission

## Pediatric study

1 in 4 affected with AKI during hospitalization (ICU)[1]

Predict AKI Risk in an Intensive Care Setting

- Urine samples
- Predict Stage 2/3 AKI

- 15 hospital sites in US clinical trial for The NGAL Test in pediatrics
- BioPorto expects to finalize pediatric trial enrollment in 1H 2022, followed by assembling the FDA submission package & De Novo application with Breakthrough Designation
- FDA targets up to 150 calendar days after submission to respond… ***excludes time for the company to respond to FDA inquiries, which can include more data generation and "stops the clock"***

1) Kaddourah A, et al. *N Engl J Med*. 2017; 376(1):11-20.

© Copyright BioPorto

# Q1 2022 Financial Results

© Copyright BioPorto

# 70% Increase The NGAL Test Sales Drives 17% Revenue Growth in Q1 2022 vs. Q1 2021

## Revenue by Quarter (DKKm)




## Revenue by Product Category (DKKm)




© Copyright BioPorto

# Strong Performance of The NGAL Test Sales in the US and ROW

US NGAL

↑ 116%

Increase in total revenue from US NGAL sales from Q1 2021 to Q1 2022

Overall NGAL

↑ 70%

Development in global sales of NGAL from Q1 2021 to Q1 2022

## NGAL Product sales by Quarter (LTM, DKKm)




© Copyright BioPorto

# DKKm 0.5 Improvement in Adjusted EBITDA Loss; Cash Position Reflects Share Issue Proceeds

## Adj. EBITDA and Cash Position (DKKm)




- Cash burn from operations and investments reduced to DKKm 17.1 (Q1 2021: DKKm 21.3) reflecting working capital management
- Cash position end-Q1 2022 of DKKm 27 strengthened with DKKm 93.1 net proceeds from share offering closed April 1, 2022

** Pro forma DKKm 93.1 net proceeds from share issue that closed April 1, 2022*

© Copyright BioPorto

# Fully Subscribed Rights Issue

- 66.9 million new shares at a price of DKK 1.50 per share
- Advance subscription commitments and guarantees from institutional investors and three largest shareholders
- Proceeds + existing cash will be used to strengthen BioPorto's capital resources and advance implementation of its strategic priorities, including:
  - the clinical trial and application to the FDA for approval of The NGAL Test for assessment of AKI in children under the age of 22 (pediatrics) in the U.S.
  - operational and quality improvements to prepare for future scale and IVDR implementation
  - general corporate purposes
  - investments in U.S. organization and marketing to prepare for The NGAL Test launch

© Copyright BioPorto

# Financial Guidance 2022

© Copyright BioPorto

# Guidance for 2022: On-track for Execution on Both Strategic & Financial Targets

| | |
|---|---|
| Revenue | Approx. DKK 24-26 million |
| EBIT loss | Approx. DKK 95-100 million |
| Adj. EBITDA loss | Approx. DKK 76-81 million |

BioPorto's performance and guidance for 2022 is based on certain assumptions described in the annual report and continues to be subject to uncertainty due to COVID-19, including continued opening of societies and the normalization of access to hospitals, research laboratories, and regulatory bodies.

© Copyright BioPorto

# Financial Calendar 2022

| | |
|---|---|
| August 17, 2022 | Q2 2022 Results |
| November 9, 2022 | Q3 2022 Results |

Contact:
Neil Goldman, Executive VP & CFO
Tim Eriksen, Investor Relations, Zenith Advisory
investor@bioporto.com

bioporto

© Copyright BioPorto